News
-
-
-
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Intellipharmaceutics International Inc. announces listing transfer from TSX to NEX due to Cease Trade Order, new stock option plan approved. Company specializes in controlled-release drugs -
-
-
-
PRESS RELEASE
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Intellipharmaceutics International Inc. announces delay in filing annual audited financial statements for the fiscal year ended November 30, 2023, due to applicable Canadian securities laws. Company working to expedite filing for compliance with OSC regulations -
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
PRESS RELEASE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics International Inc., a pharmaceutical company, has received conditional approval to list its common shares on the TSX Venture Exchange as a Tier 2 Life Science Issuer. The company's management is working to meet the listing conditions, with expectations for a seamless transition from the Toronto Stock Exchange. Intellipharmaceutics specializes in the research, development, and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix ™ technology offers a multidimensional controlled-release drug delivery platform with various product candidates in the development pipeline. The company has also issued cautionary statements regarding forward-looking information. For further details, refer to the press release.
![Accesswire](/assets/images/accesswire-inline.png)
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DuJour Media Jason Binn Celebrates Successful 12th Anniversary Cover Party with Star-Studded After-Party and Record Turnout
![EQS Group](/assets/images/eqs-group.png)
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
-
Meyer Burger makes significant progress in relocating its core business to the USA
-
BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING
-
CureVac Announces Voting Results of General Meeting
![Les Echos](/assets/images/les-echos.png)
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024. Detailed information per transaction
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024
-
imerys-24-06-2024-information-share-capital-and-voting-rights-as-of-31-may-2024